Advertisement

Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial

  • Xiaoduo FanEmail author
  • Paul Copeland
  • Shukair Nawras
  • Amy Harrington
  • Oliver Freudenreich
  • Donald C. Goff
  • David C. Henderson
Original Investigation

Abstract

Objective

This study examined the effect of adjunctive telmisartan on body metabolism in clozapine- or olanzapine-treated patients with schizophrenia.

Method

Each subject had been on stable dose of olanzapine or clozapine for at least 1 month. In a 12-week randomized, double-blind, placebo-controlled study, subjects received either telmisartan (80 mg once per day) or placebo. The homeostasis model of assessment of insulin resistance (HOMA-IR) was calculated based on fasting blood levels of insulin and glucose. Fasting blood levels of triglycerides and cholesterols, as well as serum levels of high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) were measured. The whole-body dual-energy X-ray absorptiometry (DXA) was used to assess body composition. Lipid particles were assessed using nuclear magnetic resonance (NMR) spectroscopy. All assessments were conducted at baseline and repeated at week 12.

Results

Fifty-four subjects were randomized and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). There were no significant differences between the two groups in week 12 changes for HOMA-IR or fasting triglycerides (− 0.18 ± 1.24 vs 0.39 ± 1.39, p = 0.181; − 26 ± 76 vs − 10 ± 81 mg/dL, p = 0.679, respectively) (telmisartan vs placebo). Further, there were no significant between group differences in week 12 changes for other fasting lipids, body weight, body mass index, waist circumference, as well as various measures of lipid particles (p’s > 0.100). The DXA assessment showed no significant differences between the two groups in week 12 changes for fat mass, lean mass, or total mass (p’s > 0.100).

Conclusion

In the present study, adjunctive treatment of telmisartan did not seem to improve body metabolism in schizophrenia patients receiving olanzapine or clozapine. The implications for future studies were discussed.

ClinicalTrials.gov identifier

NCT00981526.

Keywords

Telmisartan Inflammation Schizophrenia Body composition Lipids 

Notes

Funding sources

This study was supported by Grant 5K23MH082098 from the National Institutes of Health (Dr. Fan) and the NARSAD Young Investigator Award (Dr. Fan).

Compliance with ethical standards

The study was approved by the institutional review boards of the Massachusetts General Hospital (MGH) and the Massachusetts Department of Mental Health.

Conflict of interest

Dr. Fan has received research support or honoraria from Allergen, Janssen, Alkermes, Avanir, Neurocrine, and Boehringer Ingelheim. Dr. Freudenreich has received research support or honoraria from Avanir, Neurocrine, and Janssen. Dr. Goff has received research support from Avanir. Dr. Henderson has received research support from Otsuka. Drs. Song, Natarajan, Copeland, and Harrington report no competing interests.

References

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696Google Scholar
  2. Andrade C (2016) Cardiometabolic risks in schizophrenia and directions for intervention, 1: magnitude and moderators of the problem. J Clin Psychiatry 77:e844–e847PubMedCrossRefGoogle Scholar
  3. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993–1002PubMedCrossRefGoogle Scholar
  4. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M (1998) Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 47:1643–1649CrossRefGoogle Scholar
  5. Chiquette E, Ramirez G, Defronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097–2104PubMedCrossRefGoogle Scholar
  6. Chujo D, Yagi K, Asano A, Muramoto H, Sakai S et al (2007) Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 30:1205–1210PubMedCrossRefGoogle Scholar
  7. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM (2014) Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 71:1350–1363PubMedCrossRefGoogle Scholar
  8. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R (2004) Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 27:457–464PubMedCrossRefGoogle Scholar
  9. Glickman SG, Marn CS, Supiano MA, Dengel DR (2004) Validity and reliability of dual-energy X-ray absorptiometry for the assessment of abdominal adiposity. J Appl Physiol 97:509–514PubMedCrossRefGoogle Scholar
  10. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA et al (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45–53PubMedCrossRefGoogle Scholar
  11. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL et al (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975–981PubMedCrossRefGoogle Scholar
  12. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E et al (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62:19–28PubMedCrossRefGoogle Scholar
  13. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Eden Evins A, Goff DC (2009) A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 119:457–465PubMedPubMedCentralCrossRefGoogle Scholar
  14. Hermans MP, Levy JC, Morris RJ, Turner RC (1999) Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42:678–687PubMedCrossRefGoogle Scholar
  15. Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, Lim SY, Lim DS (2007) Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 100:1625–1629PubMedCrossRefGoogle Scholar
  16. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H (2005) Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 28:498PubMedCrossRefGoogle Scholar
  17. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H, Diabetes Prevention Program Research Group (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54:2404–2414PubMedCrossRefGoogle Scholar
  18. Koulouris S, Symeonides P, Triantafyllou K, Ioannidis G, Karabinos I, Katostaras T, el-Ali M, Theodoridis T, Vratsista E, Thalassinos N, Kokkinou V, Nanas I, Stamatelopoulos S, Toutouzas P (2005) Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 95:1386–1388PubMedCrossRefGoogle Scholar
  19. Kurtz TW (2006) New treatment strategies for patients with hypertension and insulin resistance. Am J Med 119:S24–S30PubMedCrossRefGoogle Scholar
  20. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988–1992CrossRefGoogle Scholar
  21. McNamara JR, Schaefer EJ (1987) Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 166:1–8PubMedCrossRefGoogle Scholar
  22. Mehta PK, Griendling KK (2006) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 26:26Google Scholar
  23. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y (2005) Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28:757–758PubMedCrossRefGoogle Scholar
  24. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40:1385–1403PubMedPubMedCentralCrossRefGoogle Scholar
  25. Navalkar S, Parthasarathy S, Santanam N, Khan BV (2001) Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37:440–444PubMedCrossRefGoogle Scholar
  26. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ (2006) Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 163:1821–1825PubMedCrossRefGoogle Scholar
  27. Otvos JD (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171–180PubMedGoogle Scholar
  28. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM (1992) Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38:1632–1638PubMedGoogle Scholar
  29. Rehman K, Akash MS (2016) Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci 23:87PubMedPubMedCentralCrossRefGoogle Scholar
  30. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B (2015) Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res 101:74–85PubMedCrossRefGoogle Scholar
  31. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225–233PubMedPubMedCentralCrossRefGoogle Scholar
  32. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VKK, O'Rahilly S (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52:910–917PubMedCrossRefGoogle Scholar
  33. Semenkovich CF (2006) Insulin resistance and atherosclerosis. J Clin Invest 116:1813–1822PubMedPubMedCentralCrossRefGoogle Scholar
  34. Shimabukuro M, Tanaka H, Shimabukuro T (2007) Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25:841–848PubMedCrossRefGoogle Scholar
  35. Spitzer RL, Williams JB, Gibbon M, First MB (1992) The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49:624–629PubMedCrossRefGoogle Scholar
  36. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003–1009PubMedCrossRefGoogle Scholar
  37. Takagi H, Umemoto T (2014) A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens 8:578–592PubMedCrossRefGoogle Scholar
  38. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M (2003) Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169:155–158PubMedCrossRefGoogle Scholar
  39. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GMC (2005) Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4:6PubMedPubMedCentralCrossRefGoogle Scholar
  40. Warnick GR, Mayfield C, Benderson J, Chen JS, Albers JJ (1982) HDL cholesterol quantitation by phosphotungstate-Mg2+ and by dextran sulfate-Mn2+-polyethylene glycol precipitation, both with enzymic cholesterol assay compared with the lipid research method. Am J Clin Pathol 78:718–723PubMedCrossRefGoogle Scholar
  41. Weston-Green K, Huang XF, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217:337–346PubMedCrossRefGoogle Scholar
  42. Weyer C, Tataranni PA, Bogardus C, Pratley RE (2001) Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24:89–94PubMedCrossRefGoogle Scholar
  43. Yamagishi S, Takeuchi M (2005) Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 64:476–478PubMedCrossRefGoogle Scholar
  44. Yamaguchi K, Tsutsumi E (2010) The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. Intern Med 49:919–923PubMedCrossRefGoogle Scholar
  45. Yamashita H, Yoda H, Maruki T, Toyoshima R (2008) Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report. Prog Neuro-Psychopharmacol Biol Psychiatry 32:308–310CrossRefGoogle Scholar
  46. Yamashita H, Yoda H, Kuroki N, Kuwabara M, Odagaki Y, Kazawa T, Toyoshima R, Maruki T (2011) Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine. Psychopharmacology 213:1–9PubMedCrossRefGoogle Scholar
  47. Zand H, Morshedzadeh N, Naghashian F. 2017. Signaling pathways linking inflammation to insulin resistance. Diabetes Metab. SyndrGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Xiaoduo Fan
    • 1
    Email author
  • Paul Copeland
    • 2
  • Shukair Nawras
    • 1
  • Amy Harrington
    • 1
  • Oliver Freudenreich
    • 3
  • Donald C. Goff
    • 4
  • David C. Henderson
    • 5
  1. 1.Psychotic Disorders ProgramUniversity of Massachusetts Medical School/UMass Memorial Medical CenterWorcesterUSA
  2. 2.Department of MedicineMassachusetts General Hospital/Harvard Medical SchoolBostonUSA
  3. 3.Schizophrenia ProgramMassachusetts General Hospital/Harvard Medical SchoolBostonUSA
  4. 4.Department of PsychiatryNew York University Medical School and Nathan Kline InstituteNew YorkUSA
  5. 5.Department of PsychiatryBoston University/Boston Medical CenterBostonUSA

Personalised recommendations